Holen Sie sich die Stockscreener-App
68.84
2.65%
1.78
Schlusskurs vom Vortag:
$67.06
Offen:
$66.89
24-Stunden-Volumen:
5.76M
Relative Volume:
2.83
Marktkapitalisierung:
$13.26B
Einnahmen:
$4.08B
Nettoeinkommen (Verlust:
$32.48M
KGV:
36.42
EPS:
1.89
Netto-Cashflow:
$16.80M
1W Leistung:
+0.42%
1M Leistung:
-3.11%
6M Leistung:
+10.39%
1J Leistung:
+13.30%
1-Tages-Spanne:
$66.89
$69.11
1-Wochen-Bereich:
$66.33
$70.88
52-Wochen-Spanne:
$50.35
$83.95
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Vergleichen Sie INCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
68.84 | 13.26B | 4.08B | 32.48M | 16.80M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte Co. (NASDAQ:INCY) Stock Position Lowered by Sanctuary Advisors LLC - MarketBeat
Incyte price target raised to $70 from $68 at Wells Fargo - Yahoo Finance
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte (NASDAQ:INCY) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Analysts Set Incyte Co. (NASDAQ:INCY) Target Price at $76.18 - MarketBeat
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Insider Selling: Incyte Co. (NASDAQ:INCY) Insider Sells 650 Shares of Stock - MarketBeat
Incyte corp principal accounting officer Tray Thomas sells $90,967 in stock - Investing.com
Incyte (NASDAQ:INCY) Earns Neutral Rating from Analysts at UBS Group - MarketBeat
Orion Portfolio Solutions LLC Purchases New Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Wellington Management Group LLP Has $4.74 Million Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte to Present at Upcoming Investor Conference - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Toronto Dominion Bank Purchases 7,812 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Public Employees Retirement System of Ohio - MarketBeat
Incyte's SWOT analysis: stock faces patent cliff as pipeline progress unfolds - Investing.com
Incyte (NASDAQ:INCY) Earns Outperform Rating from William Blair - MarketBeat
Vestcor Inc Has $174,000 Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Oppenheimer maintains $82 target on Incyte post-ASH updates - Investing.com
Incyte Co. (NASDAQ:INCY) Stake Boosted by National Bank of Canada FI - MarketBeat
Tri Ri Asset Management Corp Takes Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Continuum Advisory LLC Cuts Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Tri Ri Asset Management Corp Makes New Investment in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals - MSN
Barclays PLC Boosts Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock rises Wednesday, still underperforms market - MarketWatch
Biotech Roundup: 3 Stocks to Watch - Schaeffers Research
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma - Yahoo Finance
Incyte reports positive Phase 3 data for Zynyz for lung cancer - MSN
Incyte (INCY) Stock Drops Amid Market Volatility - GuruFocus.com
Narrow-Moat Incyte's Hematology and Dermatology Platforms Drive Growth - Morningstar
Incyte reports positive Phase 3 data for Zynyz for lung cancer (NASDAQ:INCY) - Seeking Alpha
CURE Media Group announces winners of the 2024 MPN Heroes® Recognition Program - GlobeNewswire Inc.
Janus Henderson Group PLC Has $11.31 Million Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
State Street Corp Sells 300,240 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Quantinno Capital Management LP Has $4.49 Million Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Royal London Asset Management Ltd. Decreases Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte gains amid takeover speculation - MSN
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer - Yahoo Finance
Incyte Corp. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Jacobs Levy Equity Management Inc. Trims Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Fmr LLC - MarketBeat
Verition Fund Management LLC Buys Shares of 40,467 Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Caisse DE Depot ET Placement DU Quebec - MarketBeat
Edgestream Partners L.P. Makes New Investment in Incyte Co. (NASDAQ:INCY) - MarketBeat
Erste Asset Management GmbH Buys New Shares in Incyte Co. (NASDAQ:INCY) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Incyte Corp-Aktie (INCY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tray Thomas | Principal Accounting Officer |
Dec 16 '24 |
Sale |
69.31 |
650 |
45,052 |
23,312 |
2.88%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):